OBR daily eNewsOBR Trade JournalOBR FinancePipeline Online™OBR RadarEventsBlogAdvertise

 

Today’s Featured Oncology Headlines Subscribe»

Senator Slams FDA Advisory Committee’s Avastin Decision

(Wall Street Journal Health Blog) July 29, 2010 - An FDA advisory committee’s vote to revoke the approval of Roche-Genentech’s Avastin for treating breast cancer has drawn rough words from a Republican senator. David Vitter of Louisiana called the decision “essentially government rationing.”
read article (paid subscription required) »

Dendreon’s Prostate Cancer Drug Extends Life in Published Study

(Bloomberg) July 28, 2010 - Dendreon Corp.’s prostate cancer vaccine, Provenge, extended lives by 4.1 months in a study published in the New England Journal of Medicine. The data, released previously, led to the drug’s U.S. approval in April.
read article »

Dendreon's Provenge Questioned in NEJM

(TheStreet) July 28, 2010 - The ability of Dendreon's Provenge to prolong the survival of prostate cancer patients without having any measurable effect on the tumor is called "surprising" and "hard to understand" in an editorial published Wednesday night in the New England Journal of Medicine.
read article »

 

View ALL News »

		Our free daily oncology focused e-news service. Subscribe»  |  Search Archives»

---

Oncology Business Review Feature Articles

Oncology Business Review is our industry trade journal with carefully developed, exclusive oncology industry content. SUBSCRIBE Today!

On-Currences - Jul 2010

[ read article ]

The EMR Landscape: A Review of the ASCO 2010 EHR Lab - Jul 2010

[ read article ]

Taking It Personal–When to Add Biomarkers to Treatment Guidelines - Jul 2010

[ read article ]

Read ALL Articles »   |   Read ARCHIVED Articles »

---

OBR green

Our dynamic, eco-friendly companion to our print journal Oncology Business Review. Register for OBR green today. View OBR green.

---